Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site.
The company’s drug-device combination uses hyperpolarised 129-Xenon gas to make magnetic resonance imaging (MRI) more effective in assessing lung function.
Price: 32 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
Polarean Imaging PLC's (LON:POLX) Richard Hullihen caught up with Proactive London's Andrew Scott following a recent pre-NDA meeting with the FDA. He says they're targeting the third quarter of this year to submit an NDA for its drug-device combination which uses hyperpolarised 129-Xenon gas...
Industry & services
Basic Materials
